Morgan Stanley maintains a "Neutral" rating on Oracle Corporation (ORCL.US): OCI results meet expectations, but structural margin pressure becomes a valuation constraint.
Morgan Stanley analyst Sanjit Singh maintained a "Neutral" rating and a $210 price target on Oracle in his latest report.
P has learned that Morgan Stanley analyst Sanjit Singh maintained a "Neutral" rating and a $210 price target on Oracle Corporation (ORCL.US) in his latest report. The report's title precisely captures the core contradiction of this earnings release: "OCI results meet expectations, but gross margins still need improvement."
Previously, Oracle Corporation delivered an almost impeccable fiscal 2027 first-quarter earnings report. Revenue was $19.35 billion, up 30% year over year; cloud infrastructure (OCI) revenue was $7.4 billion, surging 121% year over year; new AI cloud contracts in the quarter exceeded $30 billion; and remaining performance obligations (RPO) soared to $664 billion, surging by $209 billion year over year. However, the stock price reaction triggered by this earnings report became one of the most dramatic "deep V-shaped samples" among recent tech stocksrising nearly 8% after hours at one point, only to close down 1.74% the next day, with cumulative year-to-date declines still exceeding 20%.
When the gap between operational excellence and stock performance continues to widen, what Oracle Corporation faces is no longer the success or failure of a single earnings report, but a fundamental question about "whether the AI infrastructure business model can be accepted by Wall Street."
Morgan Stanley's "Neutral" stance is not a rejection of Oracle Corporation's AI narrative, but a cautious "wait-and-see for validation." The bank acknowledges that OCI capacity delivery is dispersed across multiple locations and does not depend on a single project; acknowledges that GPU contracts carry an average premium of 20% upon renewal, indicating the company has pricing power rather than being forced to renew; and also acknowledges that the completion of the $20 billion equity financing plan eliminated short-term equity dilution pressure.
But Morgan Stanley's core reservation is that the gross margin of the AI infrastructure business has not yet proven capable of reaching the high levels of the company's traditional software business. As cloud infrastructure revenue continues to rise as a share of the total, structural downward pressure on overall gross margin will be inevitable.
The real "elephant in the room": $28.5 billion in capital expenditure and negative $5.4 billion in free cash flow
This is the fundamental reason for the divergence between the stock price and fundamentals. Oracle Corporation's capital expenditure for the quarter soared to $28.5 billion, more than tripling from $8.5 billion in the same period last year. Free cash flow deteriorated sharply from negative $362 million in the same period last year to negative $5.4 billion. The company's debt scale has reached $125 billion.
The full-year capital expenditure guidance remains in the range of $90 billion to $95 billion. Management expects net capital expenditure of approximately $70 billion for fiscal 2027, far above $55.7 billion in the previous fiscal year.
The key question is this: when a company burns nearly $30 billion each quarter to build data centers, while revenue growth is strong but far from sufficient to cover capital consumption at this level, investors need a clear timetable for "when positive free cash flow can be generated."
Oracle Corporation's current answer is "once it enters the ramp-up phase"but how long will that take? Can the capital market's patience last until that moment?
Morgan Stanley clearly pointed out in the report that the gross margin and free cash flow conversion of the AI infrastructure business are the key variables determining whether Oracle Corporation's valuation can shift from "Neutral" to "Overweight."
Related Articles

General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.

EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.

Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint
General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.

EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.

Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint

RECOMMEND





